Please login to the form below

Not currently logged in
Email:
Password:

Pfizer reveals post Wyeth-merger structure

Pfizer has announced its plans for the structure of its research and commercial operations following its acquisition of Wyeth

Pfizer has announced its plans for the structure of its research and commercial operations following its acquisition of Wyeth.

The US giant plans to form two distinct research organisations; Dr Martin Mackay, the current leader of Pfizer Global Research & Development (PGRD), will head up the PharmaTherapeutics Research Group, which will focus on advancing both companies' small-molecule discovery legacy and Dr Mikael Dolsten, the current president of Wyeth Research, will head up the BioTherapeutics Research Group creating a broad and deep pipeline in vaccines, antibodies, proteins, peptides, nucleic acids and other novel modalities.

Pfizer chairman and CEO, Jeff Kindler, will oversee both groups, and Mackay and Dolsten will, as well as serving as presidents of their respective organisations, serve as members of Pfizer's executive leadership team.

Dr Emilio Emini, current head of Wyeth's Vaccine Research and Development, will join Pfizer as chief scientific officer, vaccine and research, along with Dr Menelas Pangalos, Wyeth's current head of discovery, who will take up the position of chief scientific officer, neuroscience research.

"Creating two distinct, but complementary, research organisations led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery," Kindler said. "This structure powerfully states our commitment to becoming the industry leader in small molecules, large molecules and vaccines. Our approach to research will fuel our discovery efforts, inspire top talent and translate into high-impact new medicines for patients."

Pfizer and Wyeth agreed a cash-and-stock transaction worth $68bn in January 2009. The companies expect the transaction to close at the end of the Q3 or during Q4 2009. Until the acquisition is complete, staff will continue in their current roles.

8th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics